• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    5/10/24 12:31:07 PM ET
    $BFRI
    $CDIO
    $GRTS
    $IOVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $BFRI alert in real time by email

    Gainers

    • Novavax (NASDAQ:NVAX) stock increased by 110.7% to $9.42 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today.
    • Portage Biotech (NASDAQ:PRTG) stock increased by 57.97% to $0.41. The market value of their outstanding shares is at $8.1 million.
    • ITeos Therapeutics (NASDAQ:ITOS) stock rose 46.92% to $17.91. The company's market cap stands at $644.1 million. As per the press release, Q1 earnings came out today.
    • Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 37.87% to $5.25. The company's market cap stands at $86.1 million. As per the press release, Q1 earnings came out yesterday.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock increased by 34.69% to $0.98. The market value of their outstanding shares is at $21.1 million.
    • Organogenesis Hldgs (NASDAQ:ORGO) stock moved upwards by 31.79% to $3.0. The company's market cap stands at $398.3 million. The company's, Q1 earnings came out yesterday.

    Losers

    • Macrogenics (NASDAQ:MGNX) shares declined by 76.2% to $3.5 during Friday's regular session. The market value of their outstanding shares is at $218.9 million. The company's, Q1 earnings came out yesterday.
    • Revance Therapeutics (NASDAQ:RVNC) shares decreased by 26.23% to $3.17. The market value of their outstanding shares is at $329.8 million. The company's, Q1 earnings came out yesterday.
    • Biofrontera (NASDAQ:BFRI) stock declined by 24.06% to $1.2. The market value of their outstanding shares is at $6.1 million.
    • Progyny (NASDAQ:PGNY) stock declined by 20.77% to $25.75. The company's market cap stands at $2.4 billion. As per the news, the Q1 earnings report came out yesterday.
    • Iovance Biotherapeutics (NASDAQ:IOVA) shares declined by 18.18% to $11.01. The company's market cap stands at $3.0 billion. As per the news, the Q1 earnings report came out yesterday.
    • Gritstone Bio (NASDAQ:GRTS) shares decreased by 16.38% to $0.81. The market value of their outstanding shares is at $87.1 million. As per the news, the Q1 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BFRI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRI
    $CDIO
    $GRTS
    $IOVA

    CompanyDatePrice TargetRatingAnalyst
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    Progyny Inc.
    $PGNY
    1/20/2026$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Progyny Inc.
    $PGNY
    1/8/2026$34.00Hold → Buy
    Truist
    Progyny Inc.
    $PGNY
    12/9/2025$29.00Overweight
    Barclays
    Progyny Inc.
    $PGNY
    11/12/2025$30.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Novavax Inc.
    $NVAX
    10/24/2025$18.00Overweight
    Cantor Fitzgerald
    MacroGenics Inc.
    $MGNX
    9/17/2025$3.00Overweight
    Barclays
    Novavax Inc.
    $NVAX
    8/28/2025$10.00Buy
    H.C. Wainwright
    More analyst ratings

    $BFRI
    $CDIO
    $GRTS
    $IOVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sachetta Eric bought $7,620 worth of shares (2,000 units at $3.81), increasing direct ownership by 1% to 142,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    2/26/26 9:25:34 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $27,510 worth of shares (7,000 units at $3.93), increasing direct ownership by 5% to 140,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/21/25 2:28:31 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $11,250 worth of shares (2,500 units at $4.50), increasing direct ownership by 2% to 133,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/20/25 2:03:11 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $BFRI
    $CDIO
    $GRTS
    $IOVA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BFRI
    $CDIO
    $GRTS
    $IOVA
    SEC Filings

    View All

    SEC Form 10-K filed by Sensus Healthcare Inc.

    10-K - Sensus Healthcare, Inc. (0001494891) (Filer)

    3/4/26 12:15:58 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    MacroGenics Inc. filed SEC Form 8-K: Other Events

    8-K - MACROGENICS INC (0001125345) (Filer)

    3/2/26 4:15:28 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Progyny Inc.

    144 - Progyny, Inc. (0001551306) (Subject)

    3/2/26 2:54:27 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $BFRI
    $CDIO
    $GRTS
    $IOVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Iovance Biotherapeutics upgraded by Citizens with a new price target

    Citizens upgraded Iovance Biotherapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    2/25/26 7:38:09 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Progyny upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Progyny from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    1/20/26 8:45:21 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny upgraded by Truist with a new price target

    Truist upgraded Progyny from Hold to Buy and set a new price target of $34.00

    1/8/26 9:26:52 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $BFRI
    $CDIO
    $GRTS
    $IOVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Clapp Geoffrey was granted 35,228 shares, increasing direct ownership by 123% to 63,922 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    3/4/26 5:32:38 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Chief Operating Officer Cummings Melissa B was granted 45,454 shares, increasing direct ownership by 109% to 87,121 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    3/4/26 5:32:14 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    EVP, GC Swartz Allison was granted 28,409 shares, covered exercise/tax liability with 4,393 shares and sold $119,007 worth of shares (6,856 units at $17.36), increasing direct ownership by 24% to 89,879 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    3/4/26 5:31:56 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $BFRI
    $CDIO
    $GRTS
    $IOVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MacroGenics to Participate in Upcoming Investor Conferences

    ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management team will participate in the following investor conferences in March: TD Cowen 46th Annual Health Care Conference (Boston, MA). MacroGenics' President and CEO, Eric Risser, will participate in a hybrid presentation and fireside chat on Tuesday, March 3, at 3:10 pm ET. MacroGenics' management will also participate in one-on-one meetings.Leerink Partners 2026 Global Healthcare Conference (Miami, FL). Mr. Risser will participate in a fireside chat on

    2/26/26 5:30:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax to Participate in Upcoming Investor Conferences

    GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), today announced that it will participate in the following upcoming investor conferences:TD Cowen 46th Annual Health Care Conference:Fireside ChatDate:Tuesday, March 3, 2026Time:2:30 p.m. Eastern Time (ET)Location:Boston, MALeerink Partners 2026 Global Healthcare Conference:Fireside ChatDate:Tuesday, March 10, 2026Time:3:40 p.m. ETLocation:Miami Beach, FLJefferies Biotech on the Beach Summit:Investor MeetingsDate:Wednesday, March 11, 2026Location:Miami Beach, FLA webcast of the fireside chats will be available through the Events and Presentations page of the Company's website at ir.novavax.com. A replay of each webc

    2/26/26 4:30:00 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

    CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million for the fourth quarter of 2025, an increase of $98.4 million compared to net product revenue of $126.7 million for the fourth quarter of 2024. Net product revenue for the fourth quarter of 2025 consis

    2/26/26 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    $CDIO
    $GRTS
    $IOVA
    Leadership Updates

    Live Leadership Updates

    View All

    Sensus Healthcare Appoints Larry Biscotti to its Board of Directors

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors. Mr. Biscotti brings more than 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in driving commercial strategy, expanding global market share and launching advanced imaging and oncology technologi

    1/7/26 8:30:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

    Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of leadership roles focused on organizational growth, team development, sales performance and operation

    11/12/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Progyny CEO Named World Economic Forum Champion for Women's Health

    NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that CEO Pete Anevski has been honored with the recognition as a Champion for Women's Health by the World Economic Forum (the Forum) and the Global Alliance for Women's Health (GAWH). The community of Champions is a distinguished group of global leaders who are playing a critical role in driving advocacy efforts, shaping policies, fostering innovation, and unlocking investments to advance women's health. The exclusive Champions community spans diverse sectors, industries, and geographies, and includes figures such as: Helen Clark, former

    10/7/25 9:30:50 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $BFRI
    $CDIO
    $GRTS
    $IOVA
    Financials

    Live finance-specific insights

    View All

    Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

    CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million for the fourth quarter of 2025, an increase of $98.4 million compared to net product revenue of $126.7 million for the fourth quarter of 2024. Net product revenue for the fourth quarter of 2025 consis

    2/26/26 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Progyny, Inc. Announces Fourth Quarter 2025 Results

    Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three- and twelve-month periods ended December 31, 2025 ("the fourth quarter of 2025" and "the full year", resp

    2/26/26 4:01:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BFRI
    $CDIO
    $GRTS
    $IOVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    12/6/24 10:11:35 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by iTeos Therapeutics Inc.

    SC 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)

    11/21/24 8:27:38 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care